Can Biome Sustain Growth After First Full-Year Profit and International Push?
Biome Australia has reported record-breaking sales revenue for FY25, driven by strong domestic demand and promising international expansion. The company is on track to deliver its first full-year net profit and meet ambitious growth targets.
- FY25 sales revenue hits $18.4 million, up 41% year-on-year
- Q4 sales exceed $5 million, with June monthly sales up 50%
- Domestic sell-through grows over 50%, Activated Probiotics leads category
- Sixth consecutive quarter of positive EBITDA expected
- On track for $75 million+ cumulative sales by FY27 under Vision 27
Record-Breaking Revenue Growth
Biome Australia Limited (ASX, BIO), a specialist in microbiome health products, has announced a landmark financial year with unaudited sales revenue reaching approximately $18.4 million for FY25. This represents a robust 41% increase compared to the previous year, underscoring the company’s accelerating momentum in the competitive probiotics market.
The final quarter of FY25 was particularly strong, with sales surpassing $5 million, a 33% uplift from Q4 FY24, and June alone delivering a record $2.1 million in sales, up 50% year-on-year. These figures translate into an annualised run rate exceeding $20 million as Biome enters FY26, signaling sustained growth potential.
Domestic Market Leadership and Brand Strength
Biome’s domestic business has been a key driver of this growth, with sell-through rates increasing by more than 50% over the year. The company’s flagship Activated Probiotics brand has solidified its position as the fastest-growing player in its category, now ranking second in total probiotic revenue within community pharmacies. This success reflects Biome’s strategic focus on practitioner education, customer service, and evidence-based product innovation.
International Expansion and Future Prospects
FY25 also marked significant groundwork for Biome’s international ambitions. The company has invested heavily in establishing operations and partnerships across Canada, Ireland, the United Kingdom, and New Zealand. These efforts culminated in securing major new retail and distribution agreements poised to fuel overseas growth in FY26 and beyond. A detailed update on these markets is expected shortly, which will be closely watched by investors eager to assess Biome’s global footprint.
Profitability Milestones and Vision 27
Alongside revenue growth, Biome anticipates reporting its sixth consecutive quarter of positive EBITDA and its inaugural full-year net profit in FY25. This financial milestone aligns with the company’s Vision 27 strategy, which targets cumulative sales exceeding $75 million by FY27. Founder and Managing Director Blair Vega Norfolk highlighted the company’s rapid growth pace, noting that Biome is outpacing category expansion by 7 to 10 times and remains committed to long-term profitability and innovation.
As Biome transitions into FY26, the combination of strong domestic sales, expanding international partnerships, and improving profitability sets the stage for continued momentum in the evolving probiotics sector.
Bottom Line?
Biome’s record sales and profitability signal a turning point, but international execution will be key to sustaining growth.
Questions in the middle?
- How will Biome’s international partnerships translate into revenue in FY26?
- Can Activated Probiotics maintain its rapid growth amid increasing competition?
- What impact will achieving net profit have on Biome’s investment and expansion strategies?
